The U.S. Food and Drug Administration (FDA) has approved Edwards Lifesciences’ SAPIEN 3 platform for patients with asymptomatic severe aortic stenosis, marking a major advancement in cardiovascular care.
The SAPIEN 3, a transcatheter aortic valve replacement (TAVR) device, is now the first approved for patients who have not yet developed symptoms—a significant shift in the treatment landscape for this life-threatening condition.
This approval follows the results of the EARLY TAVR clinical trial. This landmark study randomly assigned patients with asymptomatic severe aortic stenosis to either receive TAVR or remain under standard observation.
The findings were compelling. After a median follow-up of 3.8 years, only 26.8% of the 455 patients in the TAVR group experienced death, stroke, or hospitalization due to cardiovascular causes. In contrast, 45.3% of the 446 patients in the observation group encountered these adverse outcomes.
Experts at the Gagnon Cardiovascular Institute at Morristown Medical Center in New Jersey are urging an immediate update to existing TAVR treatment guidelines. They argue that the current approach—waiting for symptoms to appear before intervening—may no longer be appropriate.
Citing the EARLY TAVR trial, these specialists highlight that symptoms in aortic stenosis can arise suddenly and unpredictably, putting patients at increased risk.
They stress that early intervention could significantly improve these patients’ outcomes and quality of life.
